Dandrit, measuring up the competition

By On 25. June 2012 · Leave a Comment · In DanDrit

Dandrit is given a chance to measure up the competition at the  Cancer Vaccine Conference in Boston late june…

Speakers are amongst others: dendreon,  Bristol-Myers Squibb,  Immunovaccine, Novartis, AstraZeneca, all among the top tier cancer vaccine companies of the world

the whole program is available here:

http://medicoinvestor.com/wp-content/uploads/2012/06/agenda.pdf

DanDrit will be represented by Dr. Eric Leire, who will be talking about challenges and design of  phase II Clinical Trials, and participating in a panel discussion afterwards

This is a pat on the shoulder and a major acknowledgement of the potential of Dandrit… I suspect this will be followed this week by the completion of the Due Dilligence of Dandrit.

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. Dandrit – a new Dendreon ? Sure looks like it ! Dandrit strengthens its European Patent base. This company has potential...
  2. Dendritic Cells explained, Provenge, Dandrit Dandrit ‘s technique is based on Dendritic Cells,  garland science...
  3. While we wait for Dandrit and DKTI As some of you know, Dandrit is planning a merger...
Tagged with: • • • • • •
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.